Acute Pancreatitis Following VAD Chemotherapy Combination Consisting Of Vincristine, Doxorubicin, And Dexamethasone In A Newly Diagnosed Multiple Myeloma Patient: A Case Report.
Author(s) -
Pervin Topçuoğlu,
Serkan Öcal,
Emre Yıldırım,
Reskan Altun
Publication year - 2012
Publication title -
the internet journal of oncology
Language(s) - English
Resource type - Journals
ISSN - 1528-8331
DOI - 10.5580/2b68
Subject(s) - dexamethasone , medicine , vincristine , multiple myeloma , doxorubicin , acute pancreatitis , chemotherapy , pancreatitis , oncology , cyclophosphamide
Background/Aims: The frequency of drug-related gastrointestinal adverse effects, including pancreatitis, has increased with the development and use of chemotherapeutic agents. Methods: In our country, a combination of vincristine, doxorubicin, and dexamethasone is frequently used as the first line of therapy in newly diagnosed multiple myeloma. A case with acute pancreatitis that we believe to depend on this therapy is presented. Results: In this case, after treatment of the acute pancreatitis episode in a very dynamic process, a proteasome inhibitor and following high dose chemotherapy with melphalan were used for the primary disease. Currently the patient is under follow-up at remission. Conclusion: It is important to consider chemotherapeutic agents as a possible etiology for acute pancreatitis in patients presenting with gastrointestinal symptoms, even after a few exposures to the agent.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom